NRx Pharmaceuticals subsidiary to acquire West Coast Interventional

Hope Therapeutics, a wholly-owned subsidiary of NRx Pharmaceuticals announced signing a non-binding letter of intent, or LOI, for acquisition of a West Coast Interventional Psychiatric Clinic. Importantly, as a component of the acquisition, the founder of the clinic, has agreed to join Hope as chief medical innovation officer. The clinic to be acquired will establish Hope’s model for clinics operating in the company’s network across the country. These treatments may include Ketamine, Spravatoa, Transcranial Magnetic Stimulation, talk therapy and other treatment options. Additionally, patients may also have access to clinical trials of new treatment modalities through these clinics.